| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0002-9343(89)80616-3 |
| P698 | PubMed publication ID | 2683767 |
| P50 | author | Chi V. Dang | Q47824561 |
| P2093 | author name string | Bell WR | |
| Dang CV | |||
| Shuman M | |||
| P2860 | cites work | Fibrinogen and fibrin | Q28267332 |
| Regulation of formation of factor XIIIa by its fibrin substrates | Q28630691 | ||
| Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors | Q28645681 | ||
| Hemostatic Abnormalities in Malignancy, a Prospective Study of One Hundred Eight Patients: Part I. Coagulation Studies | Q33462127 | ||
| Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. | Q33477337 | ||
| Molecular defects in interactions of platelets with the vessel wall | Q33477754 | ||
| "Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules | Q33822352 | ||
| Fibrin: structure and interactions | Q34276682 | ||
| Fibrinogen Philadelphia. A hereditary hypodysfibrinogenemia characterized by fibrinogen hypercatabolism | Q34462314 | ||
| Fibrinogen: a possible link between social class and coronary heart disease | Q34488611 | ||
| Congenital dysfibrinogenemia: fibrinogen detroit | Q35567541 | ||
| The effects of hepatocyte stimulating factor on fibrinogen biosynthesis in hepatocyte monolayers | Q36213532 | ||
| Regulation of major acute-phase plasma proteins by hepatocyte-stimulating factors of human squamous carcinoma cells | Q36214421 | ||
| Nucleotide sequence of the gene for the gamma chain of human fibrinogen | Q36423607 | ||
| Analysis of fibrinogen genes in patients with congenital afibrinogenemia | Q36598986 | ||
| Electron microscope structural study of modified fibrin and a related modified fibrinogen aggregate | Q36618270 | ||
| Congenital thrombotic disorders | Q39477853 | ||
| Acquired dysfibrinogenaemia in liver disease | Q39491573 | ||
| Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule | Q40153921 | ||
| Seminars in Thrombosis and Hemostasis | Q40206727 | ||
| Carboxylated calcium-binding proteins and vitamin K. | Q40283389 | ||
| Hypercoagulability and coronary artery disease | Q41308154 | ||
| Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations | Q41887737 | ||
| Heterogeneity of human fibrinogen: possible relation to proteolysis by thrombin and plasmin as studies by SDS-polyacrylamide gel electrophoresis | Q43477838 | ||
| Expression of the fibrinogen genes in rat megakaryocytes | Q48286042 | ||
| .gamma. and .gamma.' chains of human fibrinogen are produced by alternative mRNA processing | Q48388090 | ||
| Comparison of structures of various human fibrinogens and a derivative thereof by a study of the kinetics of release of fibrinopeptides | Q52688197 | ||
| Kinetics and molecular mechanism of the proteolytic fragmentation of fibrinogen | Q52704715 | ||
| Fibrinogen Baltimore IV: congenital dysfibrinogenemia with delayed fibrin monomer polymerization. | Q53687546 | ||
| Episodes of increased fibronectin level observed in a patient suffering from recurrent thrombosis related to congenital hypodysfibrinogenaemia (fibrinogen Malmoe). | Q54096022 | ||
| COVALENT STRUCTURE OF FIBRINOGEN | Q56762883 | ||
| Defect in the gamma polypeptide chain of a congenital abnormal fibrinogen (Paris I) | Q59086900 | ||
| The erythrocyte sedimentation rate. Guidelines for rational use. | Q64984999 | ||
| Fibrinogen depletion with sodium valproate | Q66699241 | ||
| Trinodular structure of fibrinogen. Confirmation by both shadowing and negative stain electron microscopy | Q66994219 | ||
| C-terminal lysine residues of fibrinogen fragments essential for binding to plasminogen | Q67276498 | ||
| Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study | Q68979773 | ||
| Fibrinogen Bergamo III and fibrinogen Torino: two further variants with hereditary molecular defects in fibrinopeptide A | Q69044137 | ||
| Fibrinogen giessen I: a congenital homozygously expressed dysfibrinogenemia with A alpha 16 Arg----His substitution | Q69188226 | ||
| In vitro preparation of nonenzymatically glucosylated human transferrin, alpha 2-macroglobulin, and fibrinogen with preservation of function | Q69382612 | ||
| Fibrinogens Kawaguchi and Osaka: an amino acid substitution of A alpha arginine-16 to cysteine which forms an extra interchain disulfide bridge between the two A alpha chains | Q69424674 | ||
| Fibrinogen Seattle II: congenital dysfibrinogenemia with an Arg (A alpha 16)----his substitution | Q69558057 | ||
| Fibrinogen Nagoya, a replacement of glutamine-329 by arginine in the gamma-chain that impairs the polymerization of fibrin monomer | Q69639578 | ||
| Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study | Q69886150 | ||
| Glycosylation of human fibrinogen in vivo | Q69940600 | ||
| Localization of segments essential for polymerization and for calcium binding in the gamma-chain of human fibrinogen | Q69990583 | ||
| Factor XIII binds to the A alpha- and B beta- chains in the D-domain of fibrinogen: an immunoblotting study | Q70037391 | ||
| Stimulation of fibrinogen synthesis in cultured rat hepatocytes by fibrinogen fragment E | Q70057494 | ||
| Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma | Q70082017 | ||
| Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the .gamma. chain | Q70211601 | ||
| Identification of a region of human fibrinogen interacting with staphylococcal clumping factor | Q70331710 | ||
| Two cases of dysfibrinogenemia characterized by abnormal FPB release: fibrinogen Madrid I & II | Q70343116 | ||
| "Fibrinogen Oklahoma": a study of interactions | Q70439796 | ||
| Fibrinogen Seattle releases half the normal amount of fibrinopeptide B | Q70450177 | ||
| Biosynthesis of dog fibrinogen. Characterization of nascent fibrinogen in the rough endoplasmic reticulum | Q70450342 | ||
| Tissue plasminogen activator: chemical and physiological aspects | Q70468659 | ||
| Phosphorylation of human fibrinogen in vitro by calcium-activated phospholipid-dependent protein kinase from pig spleen | Q70489623 | ||
| A molecular model of plasmic degradation of crosslinked fibrin | Q70565033 | ||
| A naturally occurring antibody that inhibits fibrin polymerization | Q70701763 | ||
| Influence of calcium ion on the binding of fibrin amino terminal peptides to fibrinogen | Q70708653 | ||
| γ-γ Cross-linking sites in human and bovine fibrin | Q70735278 | ||
| The structure and evolution of vertebrate fibrinogen | Q70907662 | ||
| The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease | Q70907716 | ||
| Calcium-binding regions in fibrinogen | Q70907747 | ||
| Fibrinogen heterogeneity | Q70907749 | ||
| Hereditary hypofibrinogenemia with fibrinogen storage in the liver | Q71166734 | ||
| Novel structure elucidation strategy for genetically abnormal fibrinogens with incomplete fibrinopeptide release as applied to fibrinogen Schwarzach | Q71185107 | ||
| Biochemistry of human plasminogen | Q71283013 | ||
| Beta(Leu121-Lys122) segment of fibrinogen is in a region essential for plasminogen binding by fibrin fragment E | Q71348518 | ||
| Fibrinogen as a risk factor for stroke and myocardial infarction | Q71438059 | ||
| A new type of congenital dysfibrinogenaemia with defective fibrin lysis--Dusard syndrome: possible relation to thrombosis | Q71679031 | ||
| Stimulation of fibrinogen biosynthesis by fibrinogen fragments D and E | Q71679043 | ||
| The platelet-fibrinogen interaction. Evidence for proximity of the A alpha chain of fibrinogen to platelet membrane glycoproteins IIb/III | Q72807391 | ||
| A model for fibrinogen: domains and sequence | Q93653228 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 567-576 | |
| P577 | publication date | 1989-11-01 | |
| P1433 | published in | American Journal of Medicine | Q2842959 |
| P1476 | title | The normal and morbid biology of fibrinogen | |
| P478 | volume | 87 |
| Q73154033 | Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance |
| Q40868635 | Abnormalities of hemostasis in ischemic stroke. |
| Q39451587 | Digital ischemia and gangrene due to red blood cell aggregation induced by acquired dysfibrinogenemia |
| Q81789542 | Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency |
| Q73459625 | Fibrinogen Longmont: a dysfibrinogenemia that causes prolonged clot-based test results only when using an optical detection method |
| Q40744822 | Fibrinogen: an important risk factor for atherothrombotic diseases |
| Q40725303 | Fibrinogen: its emerging role as a cardiovascular risk factor |
| Q44139418 | Functional binding analysis of human fibrinogen as an iron- and heme-binding protein |
| Q50916610 | Haemostatic and rheological factors as predictors of restenosis following percutaneous transluminal angioplasty. |
| Q45411692 | Human T-cell leukemia virus type I p30 nuclear/nucleolar retention is mediated through interactions with RNA and a constituent of the 60 S ribosomal subunit |
| Q51049444 | Human cardiomyocyte interaction with electrospun fibrinogen/gelatin nanofibers for myocardial regeneration. |
| Q39630389 | Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin |
| Q81789544 | Pharmacokinetic properties of a pasteurised fibrinogen concentrate |
| Q45056189 | Possible role for a plasma factor in the induction and/or maintenance of the state of leukocyte adhesiveness/aggregation in the peripheral blood. A study of mothers and their newborns |
| Q73515119 | The relationship of oxidized lipids to coronary artery stenosis |
Search more.